Top Stocks
Dividend Investing
ETFs
Stock Comparison
About Us
Working with TipRanks
Follow Us
Repare Therapeutics Inc (RPTX)
NASDAQ:RPTX
Repare Therapeutics (RPTX) Stock Price & Analysis
168 Followers
RPTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$8.07 - $18.68
Previous Close$12.36
Volume285.65K
Average Volume (3M)186.06K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$370.35M
Total Debt (Recent Filing)$5.89M
Price to Earnings (P/E)-16.8
Beta0.12
Next EarningsMar 01, 2023
EPS Estimate-$0.7
Next Dividend Ex-DateN/A
Dividend YieldN/A
1Y Price Target$24.75
EPS (TTM)-0.73
Shares Outstanding41,961,510
R-Squared0.00006
Standard Deviation0.16
10 Day Avg. Volume126,420
30 Day Avg. Volume186,062
Price to Book (P/B)1.70
Price to Sales (P/S)4.65
Price to Cash Flow (P/CF)57.90
P/FCF Ratio18.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside100.24% Upside
Rating ConsensusStrong Buy
Alpha-0.02
Number of Analyst Covering4
Repare Therapeutics News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RPTX FAQ
What was Repare Therapeutics’s price range in the past 12 months?
Repare Therapeutics lowest stock price was $8.06 and its highest was $18.68 in the past 12 months.
What is Repare Therapeutics’s market cap?
Currently, no data Available
When is Repare Therapeutics’s upcoming earnings report date?
Repare Therapeutics’s upcoming earnings report date is Mar 01, 2023 which is in 22 days.
How were Repare Therapeutics’s earnings last quarter?
Repare Therapeutics released its earnings results on Nov 09, 2022. The company reported $1.71 earnings per share for the quarter, beating the consensus estimate of $0.021 by $1.689.
Is Repare Therapeutics overvalued?
According to Wall Street analysts Repare Therapeutics’s price is currently Undervalued.
Does Repare Therapeutics pay dividends?
Repare Therapeutics does not currently pay dividends.
What is Repare Therapeutics’s EPS estimate?
Repare Therapeutics’s EPS estimate is -$0.7.
How many shares outstanding does Repare Therapeutics have?
Repare Therapeutics has 41,961,510 shares outstanding.
What happened to Repare Therapeutics’s price movement after its last earnings report?
Repare Therapeutics reported an EPS of $1.71 in its last earnings report, beating expectations of $0.021. Following the earnings report the stock price went up 9.178%.
Which hedge fund is a major shareholder of Repare Therapeutics?
Among the largest hedge funds holding Repare Therapeutics’s share is ARK Investment Management LLC. It holds Repare Therapeutics’s shares valued at 32M.
---
Repare Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.75
$24.75
Blogger Sentiment
Bullish
RPTX Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 155.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $7.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 2.1%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-17.60%
12-Months-Change
Fundamentals
Return on Equity
-9.80%
Trailing 12-Months
Asset Growth
38.40%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Repare Therapeutics Inc
Repare Therapeutics Inc is a precision oncology company engaged in discovery and development of novel therapeutics. The company use its proprietary, genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Using its SNIPRx platform, it is developing pipeline of SL product candidates, including its product candidate, RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations.
---
---